Medivir AB (publ) (LON:0GP7)

Market Cap	97.65M +701.6%
Revenue (ttm)	685.18K +144.0%
Net Income	-7.61M
EPS	-0.05
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	74,060
Average Volume	149,570
Open	2.345
Previous Close	2.475
Day's Range	2.300 - 2.345
52-Week Range	0.404 - 2.875
Beta	0.33
RSI	58.12
Earnings Date	Apr 29, 2026

About Medivir AB

Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Sweden, the Nordic region, rest of Europe, and internationally. The company offers Xerclear for the treatment of labial herpes under the Zoviduo name; and Olysio to treat hepatitis C. It also develops Remetinostat, a histone deacetylase (HDAC) inhibitor that has completed Phase II studies for treating mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL), basal cell carcinoma (BCC), and squamous cell carcinoma (SCC); MIV-711...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1987
• Employees: 10
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0GP7

Financial Performance

In 2025, Medivir AB's revenue was 8.50 million, an increase of 143.97% compared to the previous year's 3.48 million. Losses were -94.40 million, -23.45% less than in 2024.

Financial numbers in SEK